Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) is reporting third quarter financial results on Monday 2nd November 2020, before market open.
According to analysts surveyed by Thomson Reuters, EGRX is expected to report 3Q20 income of $ 0.28 per share from revenue of $ 47.02 million.
For the full year, analysts anticipate top line of $ 193.10 million, while looking forward to income of $ 2.19 per share bottom line.
Previous Quarter Performance
Eagle Pharmaceuticals, Inc. recorded income for the second quarter of $ 0.57 per share, from the revenue of $ 41.94 million. The quarterly earnings 32.14 percent while revenues decreased 26.03 percent compared with the same quarter last year.
Wall street analysts are predicting, EGRX to report 2Q20 income of $ 0.23 per share from revenue of $ 42.28 million. The bottom line results beat street analysts by $ 0.34 or 147.83 percent, at the same time, top line results fell short of analysts by $ 0.34 million or 0.8 percent.
Stock Performance
On Friday, shares of Eagle Pharmaceuticals, Inc. has traded high as $ 46.67 and has cracked $ 45.25 on the downward trend, reaching $ 46.52 with volume of 116.40 thousand shares.
According to the previous trading day, closing price of $ 46.52, representing a 36.63 % increase from the 52 week low of $ 33.80 and a 28.89 % decrease over the 52 week high of $ 64.94.
The company has a market capital of $ 604.76 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Eagle Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.eagleus.com
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkins lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock.
